Abuse of a Dominant Position by Pharmaceutical Undertakings in EC Law
In June 2005 the Commission imposed a &euro&semic60 million fine on AstraZeneca for abusing its dominant position. This was followed in December 2005 by the Discussion Paper on the application of Article 82 EC, issued by the Directorate-General for Competition of the European Commission. This thesis discusses the interpretation of Article 82 EC and does this from the perspective of pharmac